Hologic Inc. (HOLX) VP Sells $1,258,800.00 in Stock
Hologic Inc. (NASDAQ:HOLX) VP Karleen Marie Oberton sold 31,470 shares of the stock in a transaction dated Monday, October 10th. The stock was sold at an average price of $40.00, for a total transaction of $1,258,800.00. Following the sale, the vice president now owns 17,005 shares in the company, valued at $680,200. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Hologic Inc. (NASDAQ:HOLX) traded up 0.31% during mid-day trading on Wednesday, hitting $38.81. 1,368,877 shares of the stock traded hands. The stock has a market cap of $10.77 billion, a price-to-earnings ratio of 42.79 and a beta of 1.00. The firm’s 50-day moving average is $38.49 and its 200-day moving average is $36.32. Hologic Inc. has a 52 week low of $31.84 and a 52 week high of $41.66.
Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, July 27th. The company reported $0.51 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.48 by $0.03. The business earned $717.40 million during the quarter, compared to analyst estimates of $703.66 million. Hologic had a return on equity of 26.25% and a net margin of 9.39%. Hologic’s revenue for the quarter was up 3.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.43 earnings per share. On average, analysts forecast that Hologic Inc. will post $1.94 earnings per share for the current year.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/12/hologic-inc-holx-vp-sells-1258800-00-in-stock.html
A number of brokerages have issued reports on HOLX. RBC Capital Markets reiterated a “sector perform” rating and set a $39.00 price objective (up from $37.00) on shares of Hologic in a research note on Monday, August 1st. Leerink Swann restated an “outperform” rating and issued a $46.00 price target on shares of Hologic in a research note on Monday, October 3rd. Piper Jaffray Cos. set a $44.00 price target on shares of Hologic and gave the company a “hold” rating in a research note on Sunday, August 28th. Barclays PLC upgraded shares of Hologic from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $42.00 to $44.00 in a research note on Friday, September 23rd. Finally, Zacks Investment Research upgraded shares of Hologic from a “hold” rating to a “buy” rating and set a $43.00 price target on the stock in a research note on Wednesday, September 28th. Six analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $42.71.
A number of hedge funds have recently modified their holdings of the company. Mizuho Asset Management Co. Ltd. raised its stake in shares of Hologic by 89.9% in the second quarter. Mizuho Asset Management Co. Ltd. now owns 3,313 shares of the company’s stock valued at $115,000 after buying an additional 1,568 shares in the last quarter. J.Safra Asset Management Corp purchased a new stake in shares of Hologic during the second quarter valued at about $115,000. Invictus RG raised its stake in shares of Hologic by 577.0% in the second quarter. Invictus RG now owns 3,791 shares of the company’s stock valued at $131,000 after buying an additional 3,231 shares in the last quarter. Thompson Siegel & Walmsley LLC raised its stake in shares of Hologic by 1.2% in the second quarter. Thompson Siegel & Walmsley LLC now owns 4,176 shares of the company’s stock valued at $144,000 after buying an additional 51 shares in the last quarter. Finally, Synovus Financial Corp raised its stake in shares of Hologic by 35.6% in the second quarter. Synovus Financial Corp now owns 4,950 shares of the company’s stock valued at $171,000 after buying an additional 1,300 shares in the last quarter. 94.51% of the stock is owned by institutional investors and hedge funds.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics products include its Aptima family of assays, which run on its advanced instrumentation systems (Panther and Tigris); ThinPrep system; the Rapid Fetal Fibronectin Test, and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.